We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SW:EURONEXT PARISSodexo SA Analysis

Data as of 2026-06-14 - not real-time

$43.32

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Smurfit Westrock trades around $43, well above its DCF fair value of roughly $9, indicating a substantial valuation premium. Technical signals are mixed: the 20‑day and 50‑day SMAs sit below the current price, the MACD histogram is positive and the signal line is bullish, yet the computed trend direction is bearish and the 30‑day volatility exceeds 50%. Recent news adds nuance – the company posted a modest revenue rise in Q1 2026 and attracted a headline endorsement from George Soros, while also announcing a delisting from the LSE and seeing Barclays lower its price target to $52. Fundamentally, earnings are low with a trailing PE near 60, but forward PE drops to about 14, and cash flow generation remains positive despite a high debt‑to‑equity ratio. The dividend yield looks attractive at over 4%, but the payout ratio exceeds 200%, raising sustainability concerns. Overall, the stock appears overvalued relative to intrinsic estimates, carries elevated risk from volatility and leverage, yet retains upside potential if earnings accelerate and the market re‑prices the valuation gap.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish trend direction despite bullish MACD
  • Current price far above DCF fair value
  • Increasing trading volume suggesting market interest

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Forward EPS growth and lower forward PE
  • Barclays overweight rating and target median price above market
  • Positive operating cash flow and free cash flow generation

Long Term

> 3 years
Cautious
Model confidence: 5/10

Key Factors

  • Persistent overvaluation relative to intrinsic value
  • High leverage and debt‑to‑equity ratio
  • Unsustainable dividend payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth0.70%
Profit Margin1.22%
P/E Ratio60.2
ROE2.11%
ROA3.01%
Debt/Equity78.83
P/B Ratio1.3
Op. Cash Flow$3.4B
Free Cash Flow$1.4B

Technical Analysis

TrendBearish
RSI59.7
Support$35.53
Resistance$43.62
MA 20$40.03
MA 50$40.43
MA 200$41.03
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Fair Value$9.49
Target Price$53.46
Upside/Downside23.42%
GradeOvervalued
TypeBlend
Dividend Yield4.18%

Risk Assessment

Beta1.51
Volatility52.67%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.